Mastering Medical Coding for Monoclonal Antibody Immunization: Insights into 2024

Mastering Medical Coding for Monoclonal Antibody Immunization: Insights into 2024

Infusion services remain a vital component of medical treatment for patients across the nation, each area containing its own complexities that create challenges for coders and compliance professionals alike. In July 2023, the FDA gave the green light to Beyfortus™ (nirsevimab-alip) for infants under eight months old encountering their first respiratory syncytial virus (RSV) season and certain high-risk children aged 8–19 months entering their second RSV season. While nirsevimab acts as a preventative measure against illness, it is crucial to understand that the FDA categorizes it as a drug rather than a conventional vaccine. This classification has triggered uncertainty among medical coders regarding the appropriate CPT® code for reporting administration and how to account for counseling efforts, particularly in pediatric settings. Let’s analyze more of the specific details for accurate understanding and successful outcomes throughout 2024 and beyond.

Deciphering CPT Codes

Initially, providers were guided to use CPT code 96372 for administering nirsevimab. However, in September 2023, the CPT Editorial Panel authorized immunization administration codes 96380 and 96381, effective from October 6, 2023. Understand that these codes are not yet included in the 2024 CPT Manual but are slated for inclusion in the 2025 edition, positioned after code 96377. This update streamlines the coding process, ensuring accurate reporting of nirsevimab administrations.

ICD-10-CM Coding Clarifications

Unlike traditional vaccines, the administration of nirsevimab is not reported with the ICD-10-CM code Z23 (Encounter for immunization). Coders should understand that this diagnosis code is specific to immunization related to vaccines.

 Instead, coders should refer to Z29.11 Encounter for prophylactic immunotherapy for respiratory syncytial virus (RSV). Utilizing the correct diagnosis code is pivotal for billing accuracy, claims processing, and data integrity. Moreover, when administering nirsevimab to patients with high-risk conditions, it’s essential to append code Z29.11 alongside the relevant ICD-10-CM code corresponding to each patient’s specific high-risk condition.

The below product codes for nirsevimab became effective July 17, 2023:
CodeDescription
90380Respiratory syncytial virus, monoclonal antibody, seasonal dose; 0.5 mL dosage, for intramuscular use
90381Respiratory syncytial virus, monoclonal antibody, seasonal dose; 1 mL dosage, for intramuscular use

www.ama-assn.org/system/files/vaccine-long-descriptors.pdf

When should the above codes be reported? Assign either CPT code 90380 or 90381 on all claims for Beyfortus (nirsevimab-alip). Understand that these codes are specific to passive immunization for pediatric seasonal dose for RSVb and are differentiated by dose description of 0.5-mL dose and 1-mL. For clarity, report as one unit of 90380 when a 0.5-mL dose is administered. Report as one unit of 90381 when a 1-mL dose is administered and submit two units of 90381 when a 2-mL dose is administered.

It’s worth noting that the monoclonal antibody palivizumab carries the product code 90378 and is not to be reported with administration codes 96380 or 96381. The guidance provided by the AMA instructs healthcare providers to utilize the new CPT codes specifically designated for the administration of respiratory syncytial virus monoclonal antibody seasonal doses, outlined as 90380 and 90381. For a more comprehensive discussion on coding pertaining to the administration of vaccines or toxoids, refer to Chapter 19.

An Exclusive Offer Just for You

These are not all the tips necessary for successful infusion and injection therapy coding. Secure your copy of the 2024 Coding Essentials for Infusion & Injection Therapy Services eBook by March 29, 2024, and enjoy a $50 discount!

To take advantage of this offer, enter promo code 50EPINF24 at checkout. Don’t delay, order today!

Additional references and guidance may be found at the website of American Academy of Pediatrics:

https://www.aap.org/en/patient-care/respiratory-syncytial-virus-rsv-prevention/nirsevimab-frequently-asked-questions/

https://www.aap.org/en/patient-care/respiratory-syncytial-virus-rsv-prevention/nirsevimab-coding–payment/

Facebook
Twitter
LinkedIn

Bryan Nordley

Bryan Nordley is a seasoned professional writer, strategist, and researcher with over a decade’s worth of combined experience. Bryan launched his professional health writing career at the University of British Columbia’s Faculty of Medicine, one of the top 30 faculty of medicine programs in the world, working under the School of Public Health as a communications assistant. From there, he expanded his expertise and knowledge into private healthcare and podiatry before taking the role of healthcare writer at MedLearn Media. Bryan is the lead writer for the MedLearn Publishing brand previously producing both the acclaimed radiology and laboratory compliance manager newsletter products, while currently writing the compliance questions of the week which reach over 10,000 subscribers, creating the MedLearn Publishing Insights blogs and collaborating with operations and nationally renowned subject matter experts, in addition to serving as an editor for a variety of MedLearn publications along with marketing initiatives. Bryan continues to keep his pulse on the latest healthcare industry news, analyzing and reporting with strategic insight.

Related Stories

Leave a Reply

Please log in to your account to comment on this article.

Featured Webcasts

The Cost of Ignoring Risk Adjustment: How HCCs Impact Revenue & Compliance

The Cost of Ignoring Risk Adjustment: How HCCs Impact Revenue & Compliance

Stop revenue leakage and boost hospital performance by mastering risk adjustment and HCCs. This essential webcast with expert Cheryl Ericson, RN, MS, CCDS, CDIP, will reveal how inaccurate patient acuity documentation leads to lost reimbursements through penalties from poor quality scores. Learn the critical differences between HCCs and traditional CCs/MCCs, adapt your CDI workflows, and ensure accurate payments in Medicare Advantage and value-based care models. Perfect for HIM leaders, coders, and CDI professionals.  Don’t miss this chance to protect your hospital’s revenue and reputation!

May 29, 2025
I050825

Mastering ICD-10-CM Coding for Diabetes and it’s Complications: Avoiding Denials & Ensuring Compliance

Struggling with ICD-10-CM coding for diabetes and complications? This expert-led webcast clarifies complex combination codes, documentation gaps, and sequencing rules to reduce denials and ensure compliance. Dr. Angela Comfort will provide actionable strategies to accurately link diabetes to complications, improve provider documentation, and optimize reimbursement—helping coders, CDI specialists, and HIM leaders minimize audit risks and strengthen revenue integrity. Don’t miss this chance to master diabetes coding with real-world case studies, key takeaways, and live Q&A!

May 8, 2025
2025 Coding Clinic Webcast Series

2025 ICD-10-CM/PCS Coding Clinic Update Webcast Series

Uncover critical guidance. HIM coding expert, Kay Piper, RHIA, CDIP, CCS, provides an interactive review on important information in each of the AHA’s 2025 ICD-10-CM/PCS Quarterly Coding Clinics in easy-to-access on-demand webcasts, available shortly after each official publication.

April 14, 2025

Trending News

Featured Webcasts

The Two-Midnight Rule: New Challenges, Proven Strategies

The Two-Midnight Rule: New Challenges, Proven Strategies

RACmonitor is proud to welcome back Dr. Ronald Hirsch, one of his most requested webcasts. In this highly anticipated session, Dr. Hirsch will break down the complex Two Midnight Rule Medicare regulations, translating them into clear, actionable guidance. He’ll walk you through the basics of the rule, offer expert interpretation, and apply the rule to real-world clinical scenarios—so you leave with greater clarity, confidence, and the tools to ensure compliance.

June 19, 2025
Open Door Forum Webcast Series

Open Door Forum Webcast Series

Bring your questions and join the conversation during this open forum series, live every Wednesday at 10 a.m. EST from June 11–July 30. Hosted by Chuck Buck, these fast-paced 30-minute sessions connect you directly with top healthcare experts tackling today’s most urgent compliance and policy issues.

June 11, 2025
Open Door Forum: The Changing Face of Addiction: Coding, Compliance & Care

Open Door Forum: The Changing Face of Addiction: Coding, Compliance & Care

Substance abuse is everywhere. It’s a complicated diagnosis with wide-ranging implications well beyond acute care. The face of addiction continues to change so it’s important to remember not just the addict but the spectrum of extended victims and the other social determinants and legal ramifications. Join John K. Hall, MD, JD, MBA, FCLM, FRCPC, for a critical Q&A on navigating substance abuse in 2025.  Register today and be a part of the conversation!

July 16, 2025

Trending News

CYBER WEEK IS HERE! Don’t miss your chance to get 20% off now until Dec. 2 with code CYBER24